Related Experiment Videos
Assessing chemokine co-receptor usage in HIV
Eoin Coakley1, Christos J Petropoulos, Jeannette M Whitcomb
1ViroLogic Inc, South San Francisco, California 94080, USA.
Current Opinion in Infectious Diseases
|January 14, 2005
Summary
Accurate human immunodeficiency virus (HIV) tropism assays are essential for developing new antiviral drugs targeting CCR5 or CXCR4. These assays aid in clinical trials and selecting optimal HIV treatment strategies.
Area of Science:
- Virology
- Immunology
- Drug Development
Background:
- HIV entry relies on envelope proteins interacting with CD4 and co-receptors (CCR5 or CXCR4).
- CXCR4-tropic HIV strains correlate with increased pathogenicity and faster disease progression.
- CCR5 and CXCR4 antagonists are emerging as key antiviral agents, with trials ongoing.
Purpose of the Study:
- To highlight the critical role of HIV tropism assays in clinical trial design and patient management.
- To emphasize the need for reliable tropism determination for effective antiviral therapy selection and monitoring.
Main Methods:
- Utilizing recombinant viruses and pseudotyped HIV in tropism assays.
- Accumulating comparative data with established tropism determination methods.
- Employing tropism assays in in vitro studies and early-phase clinical trials of co-receptor inhibitors.
Main Results:
- Tropism assays using recombinant and pseudotyped HIV are increasingly adopted.
- Comparative data between new and standard tropism assays are becoming available.
- These assays support epidemiological studies and research on co-receptor inhibitors.
Conclusions:
- Rapid and reliable HIV tropism assays have accelerated the development of novel antiviral therapies.
- Establishing the role of these assays in routine clinical practice is the next crucial step.